The main facility will be used for commercial-scale production of the company’s vaccines and is said to provide twice the cGMP production capacity of their current facility.
Novavax president and CEO Stanley C Erck said the new plant would help them supply vaccines including seasonal and pandemic VLP influenza vaccines.
"In addition to cGMP facilities, these buildings will accommodate current and future clinical, R&D and administrative requirements," Erck added.